Fig. 1

TRIM25 is upregulated in glioma and associated with poor prognosis. A TRIM25 mRNA levels in non-tumor tissues (n = 4) and GBM tissues (n = 156) from TCGA (GBM) datasets (left panel); in WHO grade II (n = 226), WHO grade III (n = 244), and WHO grade IV (n = 150) glioma tissues from TCGA (LGG/GBM) datasets (middle panel); and in WHO grade II (n = 291), WHO grade III (n = 334), and WHO grade IV (n = 388) glioma tissues from CGGA datasets (right panel). B Overall survival (OS) of TRIM25 mRNA-high and TRIM25 mRNA-low patients with glioma in CGGA (n = 983) and TCGA (n = 667) datasets. C Representative images of TRIM25 IHC performed on WHO grade II–IV glioma tissues and nonneoplastic brain tissues (NBTs). Scale bar = 100 μm (top) or 50 μm (bottom). D Graphical representation of scoring performed for IHC staining of TRIM25 in primary glioma tissues and NBTs. E Western blotting analysis of TRIM25 protein levels in primary glioma tissues (n = 9) and NBTs (n = 3). ns: not significant, ∗: p < 0.05, ∗∗: p < 0.01, ∗∗∗: p < 0.001, and ∗∗∗∗: p < 0.0001